Outside of Industry, a Professor Develops K777 to Treat Chagas Disease | GenomeWeb

Jim McKerrow, a University of California, San Francisco, professor, has filed an investigational new drug application with the Food and Drug Administration — without the financial backing of a pharmaceutical company. For 20 years, McKerrow has been trying to find a treatment for Chagas disease — classified as a neglected disease — and has found what he thinks is the best hope of curing it. It's called K777, a compound originally developed for testing against cancer and inflammatory diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.